Israeli company keepMed, which is a developer of devices for treating obstructive sleep apnea, raised €13 million in a Series C financing round. In the round new investors were participated such as Celeste Management, Financière Arbevel и 4See Ventures, as well as existing investors Merieux Equity Partners, Pitango Venture Capital, Xenia Venture Capital, C4 Ventures and Lavorel Medicare.
The company has developed a unique, responsive and personalized positive airway pressure device keePAP for the treatment of obstructive sleep apnea. It is a disease characterized by recurrent episodes of upper airway obstruction during sleep and is associated with a significantly increased risk of heart diseases: diabetes and stroke, which usually includes loud snoring and fragmented non-refreshing sleep.
At the end of 2019, the company received the EU CE certificate and completed the first human test. The funds raised in this round will be used to drive keePAP clinical development towards FDA approval and market entry in the US and Europe.
The company was founded in 2012.